In addition, the overexpression of SREBP2 can lead to an alteration in insulin secretion, a reduced number of pancreatic beta cells, diabetes, low weight, increased total cholesterol (TC) in blood and tissues, and non-alcoholic hepatic steatosis [7]. Here, SREBF2 is linked to fatty liver disease.